A Phase I Open-label, Multi-dose, Dose Escalation and Dose Expansion Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
This study is testing a new oral medication called PLB1004 to see how well it treats non-small cell lung cancer. It is designed to find the safest and most effective dose for patients whose cancer is driven by specific gene changes known as EGFR mutations.
You may be eligible if you are at least 18 years old and have a confirmed EGFR mutation in your lung cancer cells. You must have recovered from any recent cancer treatments or surgeries and be in generally stable health.
Participants will take the experimental drug by mouth while the research team closely monitors their health and tracks how their cancer responds. You will attend regular check-ups to ensure the medicine is safe for you and to see how your body processes it.
This study is currently recruiting patients at medical centers in Sacramento, California; Louisville, Kentucky; and Omaha, Nebraska. It is a Phase 1 study, which means it is an early step in testing how a new treatment works in people.
- 1This trial tests a new targeted pill for specific types of lung cancer.
- 2Participation helps researchers determine the safest dose for future patients.
- 3You will receive careful monitoring and support from a dedicated medical team throughout the process.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.